摘要
目的:探讨阿托伐他汀对慢性心力衰竭患者左室射血分数(LVEF),脑利钠肽(BNP)及肿瘤坏死因子(TNF-α)、核转录因子(NF-κB)活性的影响。方法:将血脂正常的慢性心力衰竭患者50例随机分为对照组(25例)和他汀组(25例)。两组均接受常规治疗(利尿剂、ACEI、或洋地黄、β-受体阻滞剂),他汀组再加用阿托伐他汀(20mg/d)治疗,治疗前及治疗后12周均测LVEF、血清BNP、TNF-α、外周血单个核细胞NF-κB活性。结果:BNP、TNF-α、NF-κB活性与心力衰竭严重程度正相关,治疗12周后,两组TNF-α、BNP、NF-κB活性均下降(P<0.05),LVEF升高(P<0.05),且以他汀组变化更明显,与对照组比较差异有统计学意义(P<0.05)。结论:慢性心力衰竭患者在接受常规治疗的同时,加用阿托伐他汀治疗可明显改善LVEF、降低BNP、TNF-α及NF-κB活性。
Objective：To investigate the effects of atorvastatin on left ventricular ejection fraction（LVEF） ,brain natriuretic peptide（BNP）,TNF-α, nuclear factor-kappaB（NF-κB）activity in patients with chronic heart failure. Methods：Fifty chronic heart failure patients with normal blood lipids were randomly divided into control group（n = 25） and atorvastatin group（n = 25）. Control group treated with routine therapy, atorvastatin group treated with atorvastatin based on routine therapy for 12 weeks. LVEF,BNP,TNF-α and NF-κB activity in peripheral blood monoeuclear cells （PBMC） were measured 12 weeks before and after treatment. Results：Levels of TNF-α,BNP and NF-κB activity were significantly correlated with severity of cardiac function. Level of TNF-α,BNP and NF-κB activity were decreased after 12 weeks＇ treatment （P〈0. 05）. LVEF was increased compared with that before treatment in both groups, especially in atorvastatin group（P〈0.05）. Conclusion： LVEF may be further improved while TNF-α, BNP and NF-κB activity were further decreased in patients with chronic heart failure after treatment with atorvastatin on basis of routine treatment.
出处
《内科急危重症杂志》
2007年第6期289-291,共3页
Journal of Critical Care In Internal Medicine
关键词
慢性心力衰竭
阿托伐他汀
肿瘤坏死因子-Α
脑利钠肽
Chronic heart failure Atorvastatin Tumor necrosis factor-α Brain natriuretic peptide
作者简介
通讯作者：席海林，E-mail：xhl2227210@sina．com
